# Topos Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/topos-bio

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.toposbio.ai
- Total disclosed funding: $11M
- Latest round: Seed (Jan 8, 2026)
- Investors on record: 3

## About

Topos Bio, based in the US, specializes in drug discovery through its innovative AI-native platform, focusing on intrinsically disordered proteins to address complex diseases such as Alzheimer's and prostate cancer.Topos Bio, founded in 2025, operates out of San Francisco, US. The company is dedicated to drug discovery by leveraging an advanced AI-driven platform. In January 2026, Topos Bio raised USD 10.5 mn in Seed funding, co-led by Boldstart Ventures, Threshold Ventures, and Neo Ventures. This round represented the total amount raised to date.Topos Bio is focused on revolutionizing drug discovery through its advanced AI-native platform, specifically targeting intrinsically disordered proteins (IDPs), which play a significant role in diseases such as Alzheimer's and prostate cancer. The company’s flagship product, Topos-1, is an all-atom foundation model designed to generate physically realistic conformational ensembles for flexible proteins. This model enables researchers to analyze protein dynamics more effectively, unlocking new opportunities to address previously deemed "undruggable" targets in the pharmaceutical landscape. Topos Bio primarily collaborates with research institutions and biotechnology firms, including partnerships with organizations like the Gladstone Institutes. The solutions offered by Topos are particularly relevant in key pharmaceutical markets in North America and Europe, where there is a growing demand for innovative approaches in drug development.Topos Bio's revenue model is structured around partnerships and collaborations with academic institutions and biotech companies that seek to leverage its cutting-edge technology for drug discovery. The company engages in B2B transactions, focusing on providing access to its proprietary drug discovery platform and tools, including the Topos-1 model. These agreements may involve licensing fees or subscription-based access to the platform, facilitating ongoing collaboration and integration of Topos's technology into clients’ research workflows. Participation in research initiatives and partnerships with prestigious organizations enhances the company’s visibility and fosters a robust client base, further solidifying its position in the competitive biotech sector. Specific pricing structures for these services are detailed within partnership agreements, reflecting the tailored nature of their offerings.In January 2026, Topos Bio secured USD 10.5 mn in Seed funding, which will be allocated to advancing its AI-driven drug discovery platform. The company aims to refine its Topos-1 model for intrinsically disordered proteins and expand its generative chemistry capabilities. Plans include validating these advancements through wet lab experiments, targeting treatments for Alzheimer’s and cancer. Topos Bio is also exploring expansion into additional markets, particularly in Europe, to enhance its reach in pharmaceutical research by 2027.

## Funding rounds

- Seed, Jan 8, 2026, $11M — Boldstart Ventures, Neo Ventures, Threshold Ventures

## Investors

- Boldstart Ventures (https://capitalatlas.ai/funds/boldstart-ventures) — Seed
- Neo Ventures — Seed
- Threshold Ventures (https://capitalatlas.ai/funds/threshold-ventures) — Seed